• LAST PRICE
    58.3600
  • TODAY'S CHANGE (%)
    Trending Down-2.1300 (-3.5212%)
  • Bid / Lots
    58.2800/ 1
  • Ask / Lots
    58.4300/ 1
  • Open / Previous Close
    59.1800 / 60.4900
  • Day Range
    Low 57.2300
    High 59.4700
  • 52 Week Range
    Low 30.1707
    High 70.0000
  • Volume
    193,616
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 60.49
TimeVolumeAPLS
09:32 ET3204159.065
09:34 ET1180958.23
09:36 ET294858.24
09:38 ET148758.405
09:39 ET441958.4
09:41 ET162658.47
09:43 ET884258.12
09:45 ET170958.15
09:48 ET823657.405
09:50 ET1338357.4
09:52 ET550557.39
09:54 ET823957.65
09:56 ET518057.795
09:57 ET186558.385
09:59 ET1562558.625
10:01 ET648958.23
10:03 ET50058.155
10:06 ET598158.49
10:08 ET490058.4
10:10 ET301458.36
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAPLS
Apellis Pharmaceuticals Inc
6.5B
-8.6x
---
United StatesLEGN
Legend Biotech Corp
6.5B
-17.1x
---
United StatesASND
Ascendis Pharma A/S
5.6B
-16.0x
---
United StatesKRTX
Karuna Therapeutics Inc
7.4B
-32.3x
---
United StatesCYTK
Cytokinetics Inc
4.5B
-19.0x
---
United StatesGBT
Global Blood Therapeutics Inc
4.6B
-13.7x
---
As of 2022-10-05

Company Information

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that is focused on developing therapeutic compounds to treat disease through the inhibition of the complement system. The Company is developing pegcetacoplan with Sobi for systemic administration in several indications, including paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, cold agglutinin disease, and hematopoietic stem cell transplantation thrombotic microangiopathy. The Company's advanced clinical programs targeting component 3 with Phase III clinical trials of its lead product candidate, pegcetacoplan, in multiple indications. Pegcetacoplan is a conjugate of a compstatin analogue, formulated both for ophthalmological administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin.

Contact Information

Headquarters
100 Fifth AvenueWALTHAM, MA, United States 02451
Phone
617-977-5700
Fax
302-655-5049

Executives

Independent Chairman of the Board
Gerald Chan
President, Chief Executive Officer, Co-Founder, Director
Cedric Francois
Co-Founder, Chief Scientific Officer
Pascal Deschatelets
Chief Financial Officer, Treasurer
Timothy Sullivan
Chief Technical Operations Officer
Nur Nicholson

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$6.5B
Revenue (TTM)
$96.6M
Shares Outstanding
109.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.47
EPS
$-6.77
Book Value
$2.04
P/E Ratio
-8.6x
Price/Sales (TTM)
67.4
Price/Cash Flow (TTM)
---
Operating Margin
-575.44%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.